Effects of incentive spirometry with and without aerobic exercises in interstitial lung disease
Official title: Effects of Incentive Spirometry With and Without Aerobic Exercises on Dyspnea, Exercise Capacity and Quality of Life in Interstitial Lung Disease
Run by Riphah International University · NCT06133998 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether combining incentive spirometry with aerobic exercises can help people with interstitial lung disease breathe better and improve their quality of life compared to using spirometry alone.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 32 (estimated) |
| Sponsor | Riphah International University Academic / other |
| Locations | 1 site (Lahore, Punjab) |
| Trial ID | NCT06133998 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 55 diagnosed with interstitial lung disease who are clinically stable.
✕Probably not a fit
Patients with other significant respiratory disorders or comorbidities that prevent exercise training may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the impact of incentive spirometry combined with aerobic exercises versus incentive spirometry alone on patients with interstitial lung disease. It aims to assess improvements in dyspnea, exercise capacity, and quality of life among participants. The study will involve 32 patients who will be randomly assigned to either an aerobic exercise group or a control group receiving only spirometry treatment. Various assessments, including the 6-minute walk test and quality of life questionnaires, will be utilized to evaluate outcomes.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life and physical capabilities of patients suffering from interstitial lung disease.
How similar studies have gone: While similar approaches have been explored, this specific combination of incentive spirometry and aerobic exercises in interstitial lung disease is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients18 to 55 years of age (21) * Both gender(M/F) * Diagnosed as ILD ( sarcoidosis,acute interstitial pneumonia etc.)on clinical, radiological, and histopathological basis * All included patients were clinically stable without exacerbations in the past 1 month. Exclusion Criteria: * Patients with other significant respiratory disorders such as acute infections, pulmonary tuberculosis, COPD, asthma, bronchiectasis, lung carcinoma, and pneumothorax * connective tissue disease-associated ILD * Patients having other co morbid diseases preventing from exercise training, for example, disability due to orthopedic, neurological, and acute cardiac causes * Physically and mentally unwell to attend the hospital for training * Already completed or participated in a PR program in the past 1 year
Where it's running
-
Ittefaq Hospital
Lahore, Punjab, Pakistan Recruiting
Study contacts
- Principal investigator: sumera abdul hameed, Ms — Riphah International University
- Study coordinator: imran amjad, phd
- Email: imran.amjad@riphah.edu.pk
- Phone: 03324390125
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Telitacicept for primary Sjögren’s with interstitial lung disease
This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis
A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.
-
Treatment Response in Myositis-Associated RP-ILD in Adults
This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease
Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.